FIELD: biotechnology; medicine; agriculture.
SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Presented is a gene-therapeutic DNA vector based on the gene-therapeutic DNA vector VTvaf17, carrying a target gene selected from a group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 genes to increase the level of expression of this target gene in the human body and animals. Gene-therapeutic DNA vector VTvaf17-COL1A1, or VTvaf17-COL1A2, or VTvaf17-P4HA1, or VTvaf17-P4HA2, or VTvaf17-COL7A1, or VTvaf17-CLCA2, or VTvaf17-ELN, or VTvaf17-PLOD1 has nucleotide sequence SEQ ID No.1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, respectively. Invention also discloses a method of producing said vector, use of a vector, an Escherichia coli strain carrying said vector, as well as a method of producing said vector on an industrial scale.
EFFECT: invention provides the possibility of its safe application for genetic therapy of humans and animals.
22 cl, 23 dwg, 32 ex
